乙型肝炎病人重叠感染丙型肝炎的评价

应用ＥＬＩＳＡ和ＰＣＲ法检测５０２例乙肝病人血清,４０１例ＨＢｓＡｇ阳性血清中,有１１４例（２８．４％）抗－ＨＣＶ和ＨＣＶＲＮＡ双项阳性,２５例（６．２％）ＨＣＶＲＮＡ单项阳性;２１例（５．２％）抗－ＨＣＶ单项阳性。将ＨＢｓＡｇ乙肝病人分成ＨＢＶＤＮＡ,ＨＢｅＡｇ阳性组和ＨＢＶＤＮＡ,ＨＢｅＡｇ阴性组。前者抗－ＨＣＶ阳性率为１１．６％～２０．５％,ＨＣＶＲＮＡ阳性率为１６．２％～２０．５％。后者抗－ＨＣＶ阳性率为２０．２％～５５．６％,ＨＣＶＲＮＡ阳性率为２３％～６０．３％。结果说明长期携带ＨＢＶ者和慢性乙肝病人均可重叠ＨＣＶ感染。ＨＢＶＤＮＡ阳性组抗－ＨＣＶ和ＨＣＶＲＮＡ阳性率明显高于ＨＢＶＤＮＡ阳性组     

乙型肝炎病毒和丙型肝炎病毒的同步PCR扩增

介绍了一种从人血清中同步扩增和检测ＨＢＶ－ＤＮＡ和ＨＣＶ－ＲＮＡ的方法。ＨＣＶ－ＲＮＡ反转录成ｃＤＮＡ,这种ｃＤＮＡ和从ＨＢＶ中抽提出的ＤＮＡ一起,用根据ＨＢＶ、ＨＣＶ保守区序列设计的特异引物进行同步ＰＣＲ扩增,这种方法对于检测ＨＢＶ和ＨＣＶ重复感染很有用处     

逆转录-聚合酶链反应技术诊断丙型肝炎病毒感染

本文采用逆转录－聚合酶链反应（ＲＴ-ＰＣＲ）技术对２１２例住院及门诊病人其中肝病患者９８例（慢性肝炎４３例、肝炎后肝硬化４７例、原发性肝细胞癌８例）进行ＨＣＶ－ＲＮＡ检测。结果９８例慢性肝病患者血清中ＨＣＶ-ＲＮＡ-ＰＣＲ阳性２７例（２７．６％）,１１４例非肝病患者血清中ＨＣＶ-ＲＮＡ-ＰＣＲ阳性９例（７．９％）,两组间差异非常显著（Ｐ（０．０１）,各种肝病患者的ＨＣＶ-ＲＮＡ-ＰＣＲ阳性率均高于非肝病组。６８例患者同时进行了ＨＣＶ-ＲＮＡ-ＰＣＲ检测和抗－ＨＣＶ检测,２５例抗－ＨＣＶ阳性的患者中ＨＣＶ－ＲＮＡ-ＰＣＲ,２１例阳性（８４％）,４３例抗－ＨＣＶ阴性的患者中ＨＣＶ-ＲＮＡ-ＰＣＲ,９例阳性（２０．１％）、有输血及血制品史者４８例,其中ＨＣＶ-ＲＮＡ-ＰＣＲ阳性１６例（３３．３％）,１６４倒无输血史者中ＨＣＶ-ＲＮＡ-ＰＣＲ阳性２０例（１２．２％）,两组间差异非常显著（Ｐ（０．０１）。结果表明：１．ＨＣＶ感染与慢性肝病有密切联系,说明ＨＣＶ感染是慢性肝炎、肝硬化、肝癌的致病因素;２．ＨＣＶ-ＰＣＲ法具有特异性好、灵敏度高、简便快速等特点,弥补了抗－ＨＣＶ检测的不足之处,是目前确定ＨＣＶ感染的主要手段;３．ＨＣＶ感染与输血关系密切,因此对献血员进行常规ＨＣＶ检测对预防由输血所致ＨＣＶ感染有着极其重要的临床意义。     

原位杂交检测石蜡包埋组织中丙型肝炎病毒RNA

为了提高ＨＣＶＲＮＡ的原位杂交检出率,我们应用地高辛标记ＨＣＶ５＇非编码区ｃＤＮＡ作探针,采用原位分子杂交法对９６Ｎ肝硬变,１０２例肝细胞肝癌进行了ＨＣＶＲＮＡ检测,并结合不同年份标本中ＨＣＶＲＮＡ的检出率,探讨ＨＣＶＲＮＡ在肝脏的分布及其丢失问题．结果显示ＨＣＶＲＮＡ定位于肝细胞和肝癌细胞胞浆内,肝脏其它细胞未见明确阳性杂交信号。ＨＣＶＲＮＡ杂交阳性细胞呈灶状和弥漫分布,正常对照、替代、空白对照为阴性,在不同年份肝硬变及肝细胞肝癌中两两比较表明新近包埋蜡块组织较陈旧蜡块组织ＨＣＶ　ＲＮＡ检出率明显高。本文结果证实ＨＣＶＲＮＡ存在于肝细胞和癌细胞的胞浆内,未见肝内其它细胞阳性,还发现ＨＣＶＲＮＡ在肝硬变、肝细胞癌中的检出率随保存时间的延长,其阳性检出率明显降低,表明ＨＣＶＲＮＡ在蜡块中存在明显的降解,应尽可能选用近期标本、为临床分析ＨＣＶ感染,ＨＣＶ与肝硬变、肝细胞肝癌的关系提供更客观的数据。     

丙型肝炎病毒RNA打点杂交检测方法同RT－PCR方法的比较

采用ＨＣＶ基因组结构区Ｃ区ｃＤＮＡ探针和非结构区ＮＳ３－４区ｃＤＮＡ探针,建立了用打点杂交（ｄｏｔｂｌｏｔｈｙｂｒｉｄｉｚａｔｉｏｎ）检测血清中ＨＣＶＲＮＡ的方法,同采用ＨＣＶ基因组５’端非编码区的一对寡核苷酸引物通过逆转录－聚合酶链式反应（ＲＴ－ＰＣＲ）检测血清中ＨＣＶＲＮＡ的方法相比较,发现两种方法都能快速早期和特异地检出血清中ＨＣＶＲＮＡ,但ＲＴ－ＰＣＲ法敏感性优于ＲＮＡ打点杂交法。对于无血清学指标的慢性ＮＡＮＢ肝炎病人的诊断,可采用这两种方法。这两种方法的敏感性在很大程度上依赖于引物和探针的敏感性,以及ＲＮＡ提取方法。ＲＴ－ＰＣＲ法适用于诊断病毒血症和复制,打点杂交法适用于研究ＨＣＶＲＮＡ量的变化,对治疗的评价,以及为实验筛选较高滴度的ＨＣＶＲＮＡ阳性样本。     

两例丙型肝炎病毒(HCV)和乙型肝炎病毒(HBV)重叠感染者的HCV核心区cDNA序列分析

从临床肝病患者中选择两例ＨＣＶ和ＨＢＶ重叠感染者ＨＳＱ和ＳＺＨ,他们血清中的生化指标丙氨酸转氨酶（ＡＬＴ）持续异常,肝活检病理示有严重的肝损伤。在ＡＬＴ异常期,血清学检测结果为ＨＢｓＡｇ、ＨＢｅＡｇ阳性,抗ＨＣＶＩｇＧ（包括Ｃ２２、Ｃ３３ｃ）阴性,但套式ＰＣＲ检测ＨＣＶＲＮＡ阳性,核心区ｃＤＮＡ序列分析发现该区有１个密码子（ＧＧＣｎｔ３８５—３８７）缺失,对应缺失的氨基酸是甘氨酸（ＧＬＹ）,从血清学检测和序列分析结果推测,在ＨＣＶ和ＨＢＶ重叠感染中,ＨＢＶ和ＨＣＶ均可处于持续复制状态,抗ＨＣＶＩｇＧ抗体阴性可能是ＨＣＶ的多蛋白前体翻译和病毒颗粒装配受到ＨＢＶ干扰的结果。     

丙型肝炎病毒PNA打点杂交检测方法同RT—PCR方法的比较

采用ＨＣＶ基因组结构区Ｃ区ｃＤＮＡ探针和非结构区ＮＳ３－４区ｃＤＮＡ探针,建立了用打点杂交检测血清中ＨＣＶ ＲＮＡ的方法,同采用ＨＣＶ基因组５＇端非编码区的一对寡核苷酸引物通过逆转录－聚合酶链式反应检测血清中ＨＣＶ ＲＮＡ折方法相比较,发现两种方法都能快速早期和特异的检出血清中ＨＣＶ ＲＮＡ,但ＲＴ－ＰＣＲ法敏感性优于ＲＮＡ打点杂交法。对于无血清学指标的慢性ＮＡＮＢ肝炎病人的诊断,可采用这两种方法     

一种新型丙型肝炎病毒培养方法的建立

以丙肝病毒 (ＨＣＶ)为切入点 ,建立一套通过基因操作技术在体外细胞培养系统中生产高滴度反转录病毒颗粒的大规模病毒培养技术平台 ,并将该技术应用于其它难以体外大规模培养的反转录病毒的生产。该体系包括一株插入Ｔ7ＲＮＡ聚合酶基因的重组痘苗病毒ｖＴＦ 3和 2个重组质粒 ,质粒ＰＴ7ＨＣＶ在上游Ｔ7启动子和Ｔ7终止子之间插入ＨＣＶ基因组ｃＤＮＡ ,可通过Ｔ7ＲＮＡ聚合酶指导转录产生 9 5ｋｂ的ＨＣＶＲＮＡ ;另一质粒Ｐ...     

HCV5＇端非编码区cDNA的体外转录

采用逆转录聚合酶链反应（ＲＴ－ＰＣＲ）从广东省一例慢性丙型肝炎病人血清中获得丙型肝炎病毒（ＨＣＶ）５＇端非编码区（５＇ＮＣＲ）３０２ｂｐ的ｃＤＮＡ片段,经补齐和提纯后插入ｐＵＣ１９质粒,获得的重组体ｐＵＮ进行序列测定。将ｐＵＮ的目的基因亚克隆进体外转录载体ｐＳＰＯＲＴＩ多克隆位点的ＥｏｏＲＩ和ＰｓｔＩ切点之间,所得重组体ｐＳＮ线性化后由Ｔ＿７ＲＮＡ多聚酶及ＳＰ６ＲＮＡ多聚酶引导体外转录反应,产物经凝胶电泳及特异引物ＲＴ－ＰＣＲ,证实ＳＰ６引导的是正义ＲＮＡ,Ｔ７合成的是反义ＲＮＡ,其大小分别力４２９ｂｐ和３６２ｂｐ。并证实所得ＲＮＡ力ＨＣＶ５＇ＮＣＲｃＤＮＡ转录而来。获得的ＨＣＶ５＇ＮＣＲｃＤＮＡ和ＲＮＡ在常规逆转录和ＰＣＲ步骤中用于设立有效的模板对照,对消除假用性及评估试剂有重要意义。同时,ＨＣＶ５＇ＮＣＲ体外转录载体的构建可用于制各ＲＮＡ探针和反义ＲＮＡ,改进后还可作为定量ＰＣＲ的竞争性模板。     

血清检测抗-HCV和用HCV RNA筛查献血员HCV感染者的研究

为了证实在献血员中筛查献血员ＨＣＶ感染血清标志物的必要性，对５００名献血员进行血清抗－ＨＣＶ检测，阳性１４例（２８％），弱阳性１６例（３２％），对１６例弱阳性供血者加查ＨＣＶＲＮＡ，７例阳性。提示，对供血者常规筛查ＨＣＶ血清标志是必要的。     

SABC法和胶体金标免疫电镜观察 体外感染细胞中HCV-NS5的表达

To study the expression of HCV non-structure 5 antigen in vitro, a human HepG2 cell line was incubated with a HCV RNA positive serum. The S ABC i mmunological techniques and gold-labeled colloid electron microscopy method wer e employed to examine for the viral proteins in those cells. The HCV non-struct ure 5 antigen was first detected in the HepG2 cells at 72 hours post incubation. The antigen was continuously observed in the cytoplasm or on the membrane as we ll on the cell wall of the HepG2 cells even after 1, 2, 3 and 4 weeks post incub ation. The observation of HCV non-structure 5 antigen continuously expressed in the HepG2 cells strongly indicates that the cells may have been infected by HCV virus and the virus may have replicated in the cells. Therefore, the HepG2 cell line may be served as a potential host for establishment of HCV infection and p ropagation in vitro.     

肝癌细胞系（HepG2）感染HCV RNA的研究

为建立丙型肝炎病毒（HCV）体外感染和细胞培养系统,用定量的HCV RNA阳性血清感染人肝癌细胞系（HepG2细胞系）,应用地高辛标记HCV RNA探针原位杂交技术和RT－PCR方法对感染后的细胞和上清液听 HCV RNA进行了检测。在感染后的第一代至第七代的细胞中出现特异性杂交阳性信号,第一代、第二代和第六代检测出HCV RNA正链,并在感染后第一、二代检测出HCV RNA负链。显示HCV不仅能在体外感染HepG2细胞系,而且在基因的复制,证明HepG2细胞能作为HCV的体外细胞培育系。     

Enhancement of hepatitis C virus replication by Epstein-Barr virus-encoded nuclear antigen 1.

Based on our recent observation that Epstein-Barr virus (EBV) is detected in 37% of the tissues of hepatocellular carcinoma, and especially frequently in cases with hepatitis C virus (HCV), the effect of EBV infection on the replication of HCV was investigated. EBV-infected cell clones and their EBV-uninfected counterparts in cell lines MT-2 (a human T-lymphotropic virus type I-infected T-cell line), HepG2 (a hepatoblastoma cell line) and Akata (a Burkitt's lymphoma cell line) were compared in terms of their permissiveness for HCV replication following inoculation of HCV derived from patients who were HCV carriers. The results indicated that EBV-infected cell clones, but not their EBV-uninfected counterparts, promoted HCV replication. EBV-encoded nuclear antigen 1 (EBNA1), which is invariably expressed in EBV-infected cells, supported HCV replication. Deletion analysis of the EBNA1 gene showed good correlation between transactivation activity and the activity supporting HCV replication. The present findings suggest that EBV acts as a helper virus for HCV replication.     

Hepatitis C virus replication in stably transfected HepG2 cells promotes hepatocellular growth and tumorigenesis

HepG2 cells stably transfected with a full-length, infectious hepatitis C virus (HCV) cDNA demonstrated consistent replication of HCV for more than 3 years. Intracellular minus strand HCV RNA was present. Minus strand synthesis was NS5B dependent, and was sensitive to interferon alpha (IFN alpha) treatment. NS5B and HCV core protein were detectable. HCV stimulated HepG2 cell growth and survival in culture, in soft agar, and accelerated tumor growth in SCID mice. These mice became HCV RNA positive in blood, where the virus was also sensitive to IFN alpha. The RNA banded at the density of HCV, and was resistant to RNase prior to extraction. Hence, HCV stably replicates in HepG2 cells, stimulates hepatocellular growth and tumorigenesis, and is susceptible to IFN alpha both in vitro and in vivo.     

HepG2 cells expressing microRNA miR-122 support the entire hepatitis C virus life cycle

The liver-specific microRNA miR-122 is required for efficient hepatitis C virus (HCV) RNA replication both in cell culture and in vivo. In addition, nonhepatic cells have been rendered more efficient at supporting this stage of the HCV life cycle by miR-122 expression. This study investigated how miR-122 influences HCV replication in the miR-122-deficient HepG2 cell line. Expression of this microRNA in HepG2 cells permitted efficient HCV RNA replication and infectious virion production. When a missing HCV receptor is also expressed, these cells efficiently support viral entry and thus the entire HCV life cycle.     

Stable expression and integrated hepatitis B virus genome in a human hepatoma cell line

HepG2.2.15 cell is a widely used cell model for studying HBV (hepatitis B virus) in vitro. In these cells, the HBV genome is integrated in several sites of HepG2 cellular DNA. These multiple copies may have some influence on the cellular processes. We constructed a new plasmid, pSEH-Flag-HBV, and transfected it into HepG2 cells, and then screened it with hygromycin. We then used ELISA, PCR, and RT-PCR to detect the expression of HBV in these cell lines. A cell line that stably expressed hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) was established. Using Southern blotting analysis, we found that the HBV genome was integrated as a single copy in the cellular DNA. This cell line will be a useful alternative model for HBV studies.     

Differential Expression of Candidate Virus Receptors in Human T Lymphocytes Prone or Resistant to Infection with Patient-Derived Hepatitis C Virus

Accumulated evidence implies that hepatitis C virus (HCV) infects not only the liver but also the immune system. A lymphocyte-specific CD5 molecule was recently identified as essential for infection of T cells with native, patient-derived HCV. To assess whether the proposed hepatocyte receptors may also contribute to HCV lymphotropism, expression of scavenger receptor-class B type 1 (SR-B1), claudin-1 (CLDN-1), claudin-6 (CLDN-6), occludin (OCLN), CD5 and CD81 was examined by real-time RT-PCR and the respective proteins quantified by immunoblotting in HCV-prone and resistant T cell lines, peripheral blood mononuclear cells (PBMC), primary T cells and their subsets, and compared to hepatoma Huh7.5 and HepG2 cells. SR-B1 protein was found in T and hepatoma cell lines but not in PBMC or primary T lymphocytes, CLDN-1 in HCV-resistant PM1 T cell line and hepatoma cells only, while CLDN-6 equally in the cells investigated. OCLN protein occurred in HCV-susceptible Molt4 and Jurkat T cells and its traces in primary T cells, but not in PBMC. CD5 was displayed by HCV-prone T cell lines, primary T cells and PBMC, but not by non-susceptible T and hepatoma cell lines, while CD81 in all cell types except HepG2. Knocking-down OCLN in virus-prone T cell line inhibited HCV infection, while de novo infection downregulated OCLN and CD81, and upregulated CD5 without modifying SR-B1 expression. Overall, while no association between SR-B1, CLDN-1 or CLDN-6 and the susceptibility to HCV was found, CD5 and CD81 expression coincided with virus lymphotropism and that of OCLN with permissiveness of T cell lines but unlikely primary T cells. This study narrowed the range of factors potentially utilized by HCV to infect T lymphocytes amongst those uncovered using laboratory HCV and Huh7.5 cells. Together with the demonstrated role for CD5 in HCV lymphotropism, the findings indicate that virus utilizes different molecules to enter hepatocytes and lymphocytes.     

表达丙型肝炎病毒NS3抗原的重组腺病毒构建及体外表达

为探索研制丙型肝炎疫苗的新途径,以期获得防治丙型肝炎的重组腺病毒减毒活疫苗,我们构建了表达丙型肝炎病毒(Hepatitis C virus ,HCV)非结构蛋白3(non structural protein 3,NS3)抗原的重组腺病毒RAd NS3,并检测其在体外表达。应用PCR从真核表达质粒pRC/NS3 中扩增编码HCV NS3 蛋白(329-935aa)的基因片段,定向克隆到重组腺病毒AdEasy-1系统的穿梭质粒pAdTrack CMV上,采用细菌内同源重组"两步转化法"构建携带HCV NS3基因的重组腺病毒基因组质粒pAd HCV NS3,转染293 细胞,成功包装出重组腺病毒RAd NS3,利用它有效地感染人肝癌细胞株HepG2,经RT PCR及免疫印迹等不同方法检测表明,被感染细胞能表达HCVNS3蛋白,为后续进行重组腺病毒在动物体内诱导抗HCV免疫应答能力的研究奠定了基础。